Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  OTC Bulletin Board  >  CELLCEUTIX    CTIX

SummaryNewsCompany 
News SummaryMost relevantAll newsSector newsTweets 

Cellceutix Corp : Small Cap Stocks in Focus Today are CTIX, CWGL, FNRC and DEWM

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/29/2013 | 05:50am CEST

Cellceutix (OTC: CTIX),The Crimson Wine Group (OTC: CWGL), 1st NRG Corp. (PINK: FNRC) and Dewmar International BMC, Inc. (OTC: DEWM) are our Small Cap Stocks in focus today.

Cellceutix (OTC: CTIX) is a clinical stage biopharmaceutical company developing and commercializing innovative therapies in oncology, dermatology and antibiotic applications. Cellceutix believes it has a world class portfolio of compounds and is now engaged in advancing its existing portfolio of clinical compounds and strategic partnerships. Cellceutix's anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. Kevetrin in the laboratory has been shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations.

For our complete article on CTIX please go here: http://tinyurl.com/otcmagic-cellceutix

The Crimson Wine Group (OTC: CWGL) owns and operates boutique, estate-based wineries that produce world class wines in the finest wine growing regions of California, Oregon and Washington. With a commitment to the preeminent appellations and vineyard sites of each region, a philosophy of hand-crafted quality and with the highest respect for the land, each CWG property produces distinct varietal wines that reflect the finest characteristics of their place of origin.

For our complete article on CWGL please go here: http://tinyurl.com/otcmagic-crimson

1st NRG Corp. (PINK: FNRC) is an exploration and production company headquartered in Denver, Colorado whose activity to date has been centered on development of the Clabaugh Ranch Field, a project developing and producing coal bed methane reserves (CBM) located in the Powder River Basin of Wyoming.

On October 21 FNRC announced a New Drilling and Production Revenues for CBM Properties in Wyoming

For our complete article on FNRC please go here: http://tinyurl.com/otcmagic-fnrc

Dewmar International BMC, Inc. (OTC: DEWM) is a U.S. based new product development, manufacturing and brand management company. Established in 2003, Dewmar's primary business strategy has been in creating high profit margins with functional foods and beverages. The Company's flagship product, Lean Slow Motion Potion, whose flavors include Yella, Purp and Easta Pink, is rated as one of the top 3 national selling relaxation beverages in the U.S. market. The company has offices in Clinton, MS; Las Vegas, NV and Houston, TX.

For our complete article on DEWM please go here: http://tinyurl.com/otcmagic-dewm

OTCMAGIC is a newsletter that reports on developments in the world of penny stocks. OTCMagic is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit OTCMagic.com website, for complete risks and disclosures.

Subscribe Here: http://www.otcmagic.com/

Contact Info:

OTCMagic
info@otcmagic.com


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELLCEUTIX
03/21 Cellceutix Releases Favorable Topline Findings as Part of Interim Analysis of..
03/16 Cellceutix’s Phase 2 Drug Candidate Brilacidin Emerging as a Potential ..
03/08 Cellceutix Releases Preliminary Efficacy and Safety Data in Interim Analysis ..
03/03 Cellceutix Provides Update on Developing p53 Drug Candidate Kevetrin as an Or..
02/22 Cellceutix Phase 2 Brilacidin Trial Progresses to Highest Dose Cohort for the..
02/16 Cellceutix Reports on Q2 Fiscal 2017, Prepares for Important Clinical Milesto..
02/16 CELLCEUTIX CORP : Results of Operations and Financial Condition, Financial State..
02/10 Cellceutix Announces Initiation of Main Clinical Site for Phase 2a Trial of p..
02/09 CELLCEUTIX : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RES..
02/09 CELLCEUTIX CORPORATION (OTCMKTS : CTIX) Files An 8-K Regulation FD Disclosure
More news
Sector news : Bio Therapeutic Drugs
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Bio Therapeutic Drugs
Advertisement
Managers
NameTitle
Leo Ehrlich Chairman, CEO, CFO, Secretary & CAO
Arthur Peter Bertolino President & Chief Medical Officer
Krishna Kumar Menon Director & Chief Science Officer
Barry Schechter Independent Director
Mark Robert Tobin Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CELLCEUTIX0
AMGEN, INC.13.36%122 060
CELGENE CORPORATION6.59%95 986
GILEAD SCIENCES, INC.-5.73%88 240
REGENERON PHARMACEUTIC..1.61%39 568
ACTELION LTD24.44%29 804
More Results